GlassScriptPhysician profile
Megan E High
NPI 1326627175
$5,241.19
in general payments reported to CMS, 2019-2025
20 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $369 · 2022: $573 · 2023: $1,517 · 2024: $2,395 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,299.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,054.86 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $641.92 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $560.20 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $492.07 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $468.69 | 2023-2025 | Ingrezza |
| Lundbeck LLC | $454.59 | 2022-2025 | Rexulti |
| Alkermes, INC. | $303.41 | 2021-2024 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $255.14 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $225.27 | 2021-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $130.84 | 2021-2022 | |
| Indivior INC. | $119.46 | 2021-2024 | Sublocade |
| Vanda Pharmaceuticals INC. | $113.84 | 2024-2025 | Fanapt |
| Bausch Health US, LLC | $90.55 | 2024 | Aplenzin |
| E.R. Squibb & Sons, L.L.C. | $85.00 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $78.04 | 2023-2024 | Quviviq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $69.39 | 2022-2025 | Spravato |
| Ironshore Pharmaceuticals INC. | $38.80 | 2023 | Jornay Pm |
| Almatica Pharma LLC | $26.98 | 2023 | Loreev Xr |
| Orexo US, INC. | $17.59 | 2023 | Zubsolv |
| Eisai INC. | $14.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan High listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.